

GEMS Strategy

US Feedback: Sentiment, Korea vs. Taiwan, Stronger USD, Crowded Trades, and Russia

- **Sentiment in EM has improved, but the conviction level remains low** — Being short DM vs. EM hasn't panned out, nor have other trades which used EM as a funding source. Having been unable to make money off negative EM investments is the prime motivator of a more positive mood. Few DM investors suggested that there were real improvements in EM. Tighter money by the Fed in 2015/rising long bond yields were seen as the next opportunity to put on bearish EM trades. Some mention was made of switching out of Europe into EM for an opportunistic trade.
- **We continue to prefer Taiwan over Korea; many suggest we switch** — Taiwan has stronger earnings revisions, more ample liquidity conditions, better terms of trade and unit labour cost performance. The positives for Korea is a potential 25bps easing in monetary conditions and the passing of proposals relating to companies returning excess capital to shareholders. If this becomes law, the Korean discount should disappear. Korea has an ROIC below the EM average and a payout-to-capex ratio which is lowest in the world – not a good combination for shareholders.
- **Stronger USD fears have surfaced again** — This is a periodic event, and we are in such a period again, it would seem. In the past, a strong USD was good for DM, bad for EM. There are certain differences now vs. then: floating exchange rates, lower valuations and more CA surpluses. A stronger USD is bad for commodity exporters, as export prices tend to fall, but therefore good for those who import commodities, notably Asia. By sector, industrials/tech benefit while commodities and reflation trades lose out. CA deficit countries suffer more than those with surpluses.
- **Crowded trades are India, Brazil and Russia, Korea, Taiwan and China least** — Plenty of investors have good things to say regarding India, to the extent that the Indian overweight is now more than twice the size of the consensus next biggest overweight. For all the talk of switching out of Taiwan into Korea, both are consensus underweights, the former just more than the latter. When it comes to China, the skeptics continue to loom large – interesting in that regard, as since the election, China has outperformed India.
- **Surprisingly few questions on Russia, but our Russia overweight hasn't panned out** — Only two investors brought up Russia as a topic of discussion, and yet consensus data suggests it is an overweight – maybe not in the US, but more so in Europe. We've been with the consensus-overweight – which hasn't panned out. Yes, it looks cheap with negative implied EPS growth of 5% to perpetuity, but at present it does not look as if that number will improve. We now cut the overweight down to neutral. The beneficiaries of this move are China and Taiwan. EMEA now becomes an underweight. We remain overweight Turkey.

Markus Rosgen
+852-2501-2752
markus.rosgen@citi.com

Yue Hin Pong
+852-2501-2449
yue.hin.pong@citi.com

Mandy Ym Chan
+852-2501-2731
mandy.ym.chan@citi.com

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Certain products (not inconsistent with the author's published research) are available only on Citi's portals.


US Feedback: Sentiment, Korea vs. Taiwan, Stronger USD, Crowded Trades, and Russia

Sentiment has improved, but conviction level remains low

The improvement in sentiment towards EM is more better price driven than anything else.


Overall, sentiment towards the EM asset class has improved over the course of the first six months of the year (see Fig. 1 for our aggregate GEMS sentiment indicators). Sentiment has shifted from levels of despair towards the asset class towards a more neutral assessment of the prospects for EM. The general tone of our recent meetings with investors would confirm this. The dedicated EM investor no longer walks into the meetings with his or her head in their hands, as if they have just spent the last few days on the naughty step, nor do the DM investors quite have the confidence of earlier in the year anymore.

Figure 1. GEMs Sentiment Index and MSCI EM Forward 12M Returns



Source: MSCI, Haver, EPF, Bloomberg, Citi Research


Figure 2. GEMs Price-to-Earnings Ratio



Source: MSCI, Citi Research


What is still missing though, is a sense of conviction that the better performance of EM isn't just a fluke to be reversed at any time. Those who are of the opinion that it is all a bit of a fluke point to the time when the Fed will raise official rates – that will be the time when EM will really feel the pressure. Markets will tumble as the liquidity which has gone to EM will head for the door. More on that topic from us in the next few weeks, once we've run all the numbers. Just looking at the valuations of EM, (see Fig. 2) in terms of P/E and it is not as if there has been a re-rating of EM equities.

Figure 3. LatAm Sentiment Index and MSCI Lat AM Fwd 12M Returns



Source: MSCI, Haver, EPF, Bloomberg, Citi Research

Figure 4. Latin America Risk vs. Quality Style Index Performance



Source: Bloomberg, Citi Research

Where sentiment remains really quite risk averse is Lat Am. In the case of both Asia and EMEA, there have been returns towards a more risk-seeking investment style. Investors have begun to move their portfolios towards a higher-beta weighting and away from high weight on quality attributes. This has not been the case in Lat Am, (see Fig. 4). Post a brief bounce in favour of risk (beta and volatility), investors have again shifted back towards stocks with greater quality attributes.


Korea vs. Taiwan; time to switch out of the latter into the former?

Hard to argue with better EPS revisions in Taiwan than Korea, better liquidity and terms of trade.

We are overweight Taiwan and have a small underweight in Korea. Given the relative outperformance of Taiwan vs. Korea on more than one occasion, the question came up, "Is it time to switch?" The unusual aspect to this question is that on all the data we can get, Taiwan is still a consensus underweight. Yes, Korea is a little more so, but it is not as if Taiwan is a consensus overweight. So the idea of a switch is more of one from a smaller underweight to a larger one.

Why are we overweight Taiwan vs. Korea? First, our methodology, which is a combination of both looking for good value and then a positive signal from both the price and also EPS revision factors, puts Taiwan in the attractive quadrant (cheap and better momentum factors than the other countries) and has been for a while. Korea on the other hand, is as cheap/expensive as all the other markets, but has worse momentum (see Fig. 5).

Figure 5. GEMs Radar: Value and Momentum Scores by Market




Source: Citi Research

One of the aspects of momentum where Korea scores poorly – this is the second point – is earnings revisions (see Fig. 6) when we look at those of Korea and Taiwan. Taiwan has outright upward revisions to earnings, whilst Korea does not. Nor is it as simple as just to say that EPS revisions in Korea are poor, and hence there will be a rebound any moment now. With the Korean consensus according to IBES still forecasting 18.6% earnings growth, the risk to further earnings


disappointments looms larger for Korea than Taiwan. The latter is doing well on the component side, whilst Korea at the moment is struggling.

Figure 6. Earnings Revisions Index of Korea and Taiwan



Source: IBES, Citi Research


Figure 7. Terms of Trade in Korea and Taiwan



Source: Haver, Citi Research


Part of the struggle which Korea is facing is twofold. The first (see Fig. 7) is that the terms of trade in Taiwan have been better than those of Korea. Yes, in the case of Korea they have stopped declining as of late, but in the case of Taiwan, the terms of trade have actually been rising. In the case of Korea, from a low base, things are no longer getting worse, whilst in the case of Taiwan, from a high base, they are actually getting better. Now this ultimately matters, as it will get reflected in the level of corporate profitability. Linked to the topic of earnings is also the whole issue of unit labour cost.

Figure 8. Unit Labor Cost in Korea and Taiwan



Source: Haver, Citi Research

Figure 9. Free Cash Flow Margins of Korea and Taiwan



Source: Worldscope, FactSet, Citi Research


In that regard again, Taiwan is doing better at present than Korea (see Fig. 8). Between 1996 to 2000, the unit labour costs in both countries progressed at the same pace. Since then, Korea has seen its unit labour cost rise by 2.75% p.a., whilst in the case of Taiwan, unit labour cost have fallen by -1.51% p.a. Taiwan has been getting more cost competitive, whilst Korea has not. Hence the increased pressure on the BOK to cut rates – the Citi view is 25bps – in order to weaken the currency.

Worse terms of trade and rising unit labour costs is mirrored by what is happening with the free cash flow margins – the third reason (see Fig. 9). In the case of Korea,

the free cash flow margin is rolling over, whilst in the case of Taiwan, the free cash flow margins are increasing, which ultimately spells better dividends for Taiwan shareholders vs. those of Korea.

So what would it take to make us switch? First, relative value and then better revisions. There is one area which has even been getting the attention of the Korean government, and that is the issue of dividends. One area where Korea lags quite significantly is returning cash to shareholders. The other is that ROIC in Korea is lagging that of the other Ems. The two are clearly not a great combination for multiples going forward (see Fig. 10).

Figure 10. Cross Section Comparison of ROIC vs. Capex-to-Payout Ratio



Source: Factset, Citi Research

Anything which forces companies to return more cash to shareholders and invest less will be a +ve for Korea.

As such, any move by the government to successfully increase the cash which goes back to shareholders and leads to an increase in the ROIC of Korea would be welcome for investors. Should the current push prove successful, then we suspect the Korea discount would be a thing of the past. Until then, the market trades at a discount for a good reason. Note Taiwan returns more to shareholders than the average EM country and enjoys an above-average ROIC.

What if the USD rallies? That will be bad for EM

A USD rally has historically been negative for EM, but that was before floating exchange rates and a big valuation discount.

The USD question is back in vogue. USD is bad for EM, and that will bring the asset class down again. So yes, if either you or you know of someone who has a very good track record of calling the USD, then a stronger USD has tended to be bad for EM (see Fig. 11) for the USD vs. EM relationship. Note though that unlike in the prior cycle, it isn't as if the USD has been particularly strong, and yet EM in this case vs. the US has seen a very significant underperformance. Why is it the case that the USD has had such a strong impact on EM?


Figure 11. Strong US Dollar traditionally bad for GEMs Equities



Source: Datastream, CEIC, Citi Research


Historically, the USD has rallied post a prolonged period during which imbalances have been built up in EM. Current accounts have deteriorated, private sector balance sheets have become more leveraged (often with a currency mismatch attached to the rise in leverage), and overall valuations have risen. A stronger USD and the threat of higher rates makes the funding of CA deficits more difficult. A stronger USD makes the financing of foreign debt more expensive, and with the threat of higher rates, stretched valuations become unsustainable. The other factor is that a stronger USD has over time tended to be negative for commodities, which thus hits the terms of trade for the commodity producers. A higher discount rate due to moves in rate expectations and reduced earnings power regrettably depresses the NPV of future earnings, and hence equities de-rate. One country's worsening terms of trade though is another's improving terms of trade – higher rates on the back of stronger growth bodes well for the asset turn business model, but poorly for the low-asset-turn high-margin models. The profitability baton shifts from the “reflation/commodity” trade to the manufacturing/exporter part of the equity spectrum.

Figure 12. Global Current Account Rankings



Source: CEIC, Haver, IMF, Citi Research

Figure 13. Citi Structural Reforms Index



Source: Citi Research


Large CA deficits with little in the way of reforms are especially vulnerable.

So who is the most vulnerable? See Fig. 12 for those with the biggest CA deficits. Top 3 on the list are Turkey, South Africa and Brazil. Next you have a gap with Indonesia and then India. At present, the latter two are continuing to benefit from the

political honeymoon, but they have also shown improvements in the CA deficits compared to a year ago. Those countries running CA surpluses are clearly in a much better position given that they are net creditors to the rest of the world rather than being a net debtor. What also helps is if there is a reform impetus in the country with a CA deficit – sadly not all are doing equally well (see Fig. 13).


By region, a stronger USD will be more beneficial to Asia than to Lat Am or EMEA. Lat Am and EMEA have more of a commodity tilt, and a stronger USD has tended to lead to weaker commodity rather than stronger commodity prices. Worse terms of trade for the commodity exporters is a terms of trade improvement for the commodity consumers. The terms of trade graphs we've shown above (see Fig. 7) for both Korea and Taiwan highlight that point. The end effect is that in terms of relative EPS revisions, it gives you a worse revisions dynamic in Lat Am vs. Asia (see Fig. 14).

Figure 14. Earnings Revisions of Latin America relative to AxJ



Source: IBES, Citi Research

Figure 15. Median PE of EM vs. DM stocks



Source: MSCI, Citi Research

Commodity and reflation trades lose out during periods of a stronger USD; Asia, manufacturing and technology are the relative winners.

In terms of sectors, commodities lose out due to a weaker pricing environment. The other sectors which historically struggle are the so called “reflation trade” which is comprised mostly of real estate names. Tighter money as a result of a stronger USD tends to be an issue for the sector. Another sector which tends to struggle is utilities, especially if the stronger USD is accompanied by higher long rates. The winners as we alluded to are the asset turn plays. That is comprised of the manufacturing sector (terms of trade also help here) plus stronger volumes. The other winner is technology, which in EM is effectively a manufacturing process.

So if the USD rally is now for real, EM in aggregate will struggle, but bear in mind that valuations are significantly cheaper than in prior cycle and vs. EM (see Fig. 15) where we've looked at median P/E. Secondly, unlike the prior cycle of USD strength, most EM currencies are now floating not fixed. Asia is a net beneficiary due to improving terms of trade vs. both EMEA and Lat Am. By sector, manufacturing / technology wins over commodities and reflation trades.


Most crowded and least crowded EM trades

In terms of positioning, we've used the most recent data which we published in [Fund Flow Insights - July 2014 EM funds holdings: India is the most over-weight space](#). In terms of countries (see Fig. 16), the five biggest country overweights amongst EM investors at present are India, Brazil, Russia (see below on Russia), Turkey and the Philippines. Note that the India overweight is 2.6x larger than investors next biggest overweight, Brazil. The five least preferred markets are

India, Brazil and Russia are the most liked; Korea, Taiwan and China the least.


Korea, Taiwan, China, Malaysia and Poland. In the same way that India is 2.6x more of an overweight, Korea is an 2.2x bigger underweight than the next biggest underweight which is Taiwan.

Figure 16. EM Funds Country Allocations rel. to MSCI EM



Source: MSCI, FactSet, Citi Research

Figure 17. EM Fund Sector Allocations rel. to MSCI EM



Source: MSCI, FactSet, Citi Research

By sector, there is still a bias towards a more quality/defensive posture, with the large overweight in consumer staples. The next biggest overweight is in consumer discretionary, and then we have health care – again a defensive sector. At the other end of the distribution, we have energy as investors biggest underweight, followed by materials, utilities and then financials. We continue to only have a mild overlap with the consensus. Our biggest overweight remains consumer discretionary followed by technology; then we have the financials and lastly energy. Staples is our biggest underweight vs. this being the consensus's biggest overweight.

Consumer staples, consumer discretionary and health care are the overweights; commodities, utilities and financials the underweight.

By individual stocks, Fig. 18 highlights the top 20 most overweighted stocks in EM, excluding the out-of-benchmark holding in DM stocks. We have left EM stocks which are listed in the US or EU in the sample. Fig. 19 highlights the most underweighted stocks in the EM universe. As expected, the names follow on from the various sector and country weights.

Figure 18. Top 20 Overweight Stocks in Emerging Markets

RIC	Name	Ctry	Weights in		O/U Wgts (bps)	Rating	Price
			GEM Funds	MSCI EM			
BIDU.O	Baidu	CN	2.5%	0.0%	128	1	216.05
HDFC.BO	HDFC	IN	2.4%	1.0%	59	2	1063
HDBK.BO	HDFC Bank	IN	1.3%	0.2%	51	2	829
ICBK.BO	ICICI	IN	1.2%	0.2%	45	1	1468.7
AXBK.BO	AXIS Bank	IN	0.7%	0.0%	33	1	391.85
ASII.JK	Astra Intl	ID	1.2%	0.5%	28	1	7725
INFY.BO	Infosys	IN	1.7%	1.0%	24	1	3360.8
ULTC.BO	UltraTech Cement	IN	0.5%	0.1%	23	3	2426.95
ZEE.BO	Zee Ent	IN	0.4%	0.0%	21	3	290.75
CTRP.O	Ctrip.Com	CN	0.4%	0.0%	19	-	64.03
TCS.BO	Tata Consult	IN	1.3%	0.7%	18	2	2583.5
ITC.BO	ITC	IN	0.9%	0.5%	18	1	357.5
BRTI.BO	Bharti	IN	0.5%	0.1%	17	1	373
EDU.N	New Oriental	CN	0.3%	0.0%	17	-	19.55
SCB.BK	Siam Comm	TH	0.7%	0.3%	17	1	178
SM.PS	SM Inv	PH	0.4%	0.1%	14	1	797
0322.HK	Tingyi	CN	0.5%	0.2%	13	1	22
NTES.O	NetEase.com	CN	0.3%	0.0%	13	2	84.04
TAMO.BO	Tata Motors	IN	0.5%	0.2%	13	1	447.5
TBEV.SI	Thai Beverage	TH	0.2%	0.0%	12	-	0.615

Source: MSCI, Citi Research

Figure 19. Top 20 Underweight Stocks in Emerging Markets

RIC	Name	Ctry	Weights in		O/U Wgts (bps)	Rating	Price
			GEM Funds	MSCI EM			
005930.KS	Samsung Elec	KR	4.3%	6.2%	-173	1	1312000
0939.HK	CCB	CN	1.2%	2.0%	-64	1	5.95
1398.HK	ICBC	CN	1.1%	1.8%	-57	1	5.3
0700.HK	Tencent	CN	2.9%	3.2%	-55	1	128.8
3988.HK	BoC	CN	0.7%	1.4%	-51	1	3.68
0941.HK	China Mobile	CN	1.9%	2.3%	-46	1	85.65
000660.KS	SK Hynix	KR	0.5%	1.1%	-45	1	45400
2317.TW	Hon Hai Precision	TW	0.9%	1.5%	-45	-	101.5
005490.KS	POSCO	KR	0.1%	0.8%	-41	1	338000
005380.KS	Hyundai Motor	KR	1.4%	1.7%	-36	1	244500
0386.HK	Sinopec	CN	0.6%	0.9%	-30	1	7.63
051910.KS	LG Chem	KR	0.2%	0.6%	-25	1	292000
000270.KS	Kia Motors	KR	0.2%	0.6%	-25	1	60800
035420.KS	Naver	KR	0.7%	0.9%	-22	2	756000
0857.HK	PetroChina	CN	0.8%	1.0%	-22	3	10.16
RELI.BO	Reliance Ind	IN	0.6%	0.8%	-21	2	1003.5
006400.KS	Samsung SDI	KR	0.0%	0.4%	-20	2	160000
2412.TW	Chunghwa	TW	0.2%	0.5%	-19	3	91.7
2628.HK	China Life	CN	0.6%	0.8%	-18	1	23.25
TENA.KL	Tenaga	MY	0.2%	0.4%	-18	1	12.38

Source: MSCI, Citi Research

Russia overweight hasn't panned out; cut to neutral

The rationale to own Russia at the start of the year we felt was sound. Valuation support, signs of greater shareholder value with stronger growth and hence better EPS revisions. It all looked right – until it did not. Given the current trajectory of further sanctions by both camps, the risk premium on Russian equities at best stays high, in our view, but more likely than not rises further, which would hamper performance. Equities become cheaper rather than more expensive.

Cut Russia to neutral weight.


As per Fig. 16, Russia is still an overweight market amongst EM investors. We did not meet any during this latest trip in the US, which may suggest that the overweight is more commonly held in Europe. The current weight in US investors' portfolios is between zero to neutral. For those with zero, the fear of the market becoming un-investable due to specific sanctions keeps them out. Those investors who have chosen to be neutral highlight the value component and hence the rather large risk premium. On any resolution, being zero is viewed as too great a performance risk; this particularly so as long as the market remains both in the MSCI EM index and the seventh-biggest market in EM.

The money from Russia is redeployed to both Taiwan and China. We are also now underweight energy.

By cutting Russia to neutral, we now have additional funds to allocate to other EM markets. Using our relative value vs. relative momentum combination forces us into some rather tough decisions (see Fig. 5). Does one buy expensive but generally defensive markets such as Mexico? Or do we increase the China overweight further and so have a strong value tilt, and/or add more to Taiwan which has a good combination of value and momentum? India has good momentum, but the valuations suggest that investors are paying up for that. Much of ASEAN is in the same position. Brazil remains a contrarian play – cheap, price momentum has been good this year, but the earnings revisions continue to lag. With the election due in October there is still room for plenty of volatility between now and then.

As a consequence of the reduction in the weighting of Russia, we are going to increase our overweight in Taiwan further. The market still has good momentum and compared to all others, still offers value. We have liked Taiwan since last year; it is far from a consensus overweight and as per Figure 20 supplied by Peter Kurz, our Head of Taiwan Research, the locals in particular remain quite bearish on the outlook of the market given the high put-to-call ratio. We are increasing our Taiwan weight by 2%age points to now 21%. We are now 875 bps overweight.

Figure 20. Put-Call Ratio of TAIEX



Source: Bloomberg, Citi Research

The other recipient is China, where we are also increasing our overweight further to 910 bps or a weight of 27.5%. Valuations remain favourable, the reform momentum has accelerated again as has growth, and the consensus remains underweight the market.

Asia stays an overweight for us. EMEA now becomes an underweight, with only Turkey as an overweight for us. Lat Am is also an underweight.

By sector, the reduction in our Russian overweight means we are no longer overweight in the energy sector.

Style performance and is quality still expensive vs. value

In EM, the attribute which investors have turned to thus far in 2014 has been growth. Whereas last year growth was not an attribute which investors sought – too much fear that there would be no growth – this year it has proven to being the best attribute to have followed (see Fig. 21). After growth, in second place we have value. In third, we have size – but have a look at the returns to a quality investment. Pure style returns to quality have actually been negative in both Asia and EMEA but positive in Lat Am (see also our point on this issue above). Momentum, a firm favourite in 2014, has not delivered returns in 2014 to date, especially in Asia where the factor is down 4.5%.


Figure 21. Index Style Performance Year-to-Date

7/29/2014 YTD	Growth	Value	Quality	Risk	Momentum	Size
GEM	7.0%	3.6%	0.0%	-1.0%	-2.4%	1.6%
Asia	6.1%	4.5%	-2.0%	-1.0%	-4.5%	0.5%
EM Asia	9.9%	5.9%	-2.5%	1.7%	-3.2%	1.7%
CEEMEA	-4.5%	-0.2%	-2.6%	4.4%	1.3%	1.0%
LatAm	8.5%	4.2%	5.3%	-5.8%	-0.6%	4.2%
Global	-0.3%	4.1%	-1.2%	-0.8%	-3.0%	-0.4%
NA	-2.0%	3.5%	-1.4%	5.4%	-1.6%	1.1%
Europe	-1.0%	5.8%	-1.6%	-2.3%	-0.4%	-1.6%
Japan	0.3%	0.2%	-5.0%	-9.4%	-1.7%	-7.0%
AU	-3.1%	-6.4%	-3.7%	-0.8%	0.6%	-1.1%

Source: Citi Research

There are some distinct differences between what we see happening in the EM world vs. the DM world. In EM, growth as an attribute has been rewarded, but not so in DM. In North America and Australia, this attribute has actually cost you performance. In DM, value was the way to go above all others, with the exception of Australia. In North America, risk was the way to go, posting the strongest returns as opposed to Japan, where risk proved to be the worst attribute to have owned.

Figure 22. Book Yield difference between a value and quality portfolio



Source: Worldscope, FactSet, Citi Research

Figure 23. Quarterly Performance of Index Styles 2001-2014

GEM	Average Return (2001-2014)			
	Q1	Q2	Q3	Q4
Growth	0.8%	0.3%	-0.6%	-0.3%
Momentum	1.4%	1.3%	1.0%	1.6%
Quality	0.0%	0.7%	1.1%	-0.2%
Risk	-0.6%	-0.9%	-0.9%	1.7%
Size	-0.8%	0.3%	0.3%	-0.1%
Value	2.8%	2.0%	1.5%	2.1%

Source: Citi Research

As regards the valuation differential between value to quality (see Fig. 22), at present, the differential is still favourable towards a value as opposed to a quality-


biased strategy. Nor is it the case that EM has over time rewarded quality attributes over value attributes.

In Fig. 23, we highlight on a quarterly basis of the returns of the various style strategies within EM from 2001 to 2014. The two best return quarters for quality in EM has been Q3 at +1.1% and then Q2 at 0.7%. The reason behind the strong Q3 is that in Asia in particular, Q3 at +3.5% is a very strong quality quarter. Why? In Asia, there is a very strong seasonal bias for EPS revisions and hence market weakness. August and September have historically seen the sharpest downward revisions to earnings and thus also amongst the worse market moves. As such, a quality bias has proven to be useful. Looking at it beyond that one quarter, the returns are far from stellar. Flat in Q1, plus 0.7% in Q2, Q3 as we reported +1.1% and then -0.2% in Q4.

The most consistent returns have come from a value strategy (see Fig. 23). Since 2001, each quarter has yielded positive returns with 1st quarter being the strongest at 2.8% and then the 4th quarter at 2.1%. Q3 is weakest at 1.5%, followed by Q2 at 2%. The only other strategy which has yielded positive returns consistently in each of the four quarters has been momentum, which given that half of the strategy is market returns, the consistency should not come as a surprise.


As to the other strategies, risk is a Q4 strategy; try size in the middle of the year; and growth in the early part of the year. Best way forward is a focus on value with a twist of momentum. That is exactly what we use and the reason we do is that it is what has worked, and year-to-date value continues to be the second-best return style.

Figure 24. Country Allocation in EM Model Portfolio



Source: MSCI, Citi Research

Figure 25. Sector Allocation in EM Model Portfolio



Source: MSCI, Citi Research

Figure 26. EM Model Portfolio Holding

RIC	Name	Price (local) 7/31/2014	Mkt Cap US\$mn	Ratings	Wgts (%) in MSCI EM	Model Wgts	O/U-Wgts bps	2014E PE	2014E EPS Growth (%)	2014E DivYld (%)
GEMs					100.0	100.0	0.0	8.8		3.2
EM Asia					63.2	73.5	1026			
China					19.4	27.5	806			
0939.HK	China Construction Bank	5.98	192,909	1		6.0		5.1	8.0	6.8
2380.HK	China Power International	3.26	2,825	1		3.0		6.8	12.3	6.2
0883.HK	CNOOC	13.88	79,961	1		4.0		9.6	-8.3	3.5
3988.HK	Bank of China	3.72	134,093	1		6.0		5.4	2.8	6.8
0762.HK	China Unicom	13.6	41,836	1		4.5		20.4	20.6	1.6
2777.HK	Guangzhou R&F Properties	11.44	4,757	1		2.0		5.1	0.5	6.8
1133.HK	Harbin Electric	5.24	931	1		2.0		12.2	-33.1	1.9
India					6.7	4.5	-218			
CAIL.BO	Cairn India	316.25	9,788	2		1.5		5.5	-12.5	3.6
TAMO.BO	Tata Motors	447.5	22,564	1		2.0		8.1	9.1	0.1
ICBK.BO	ICICI Bank	1468.7	28,051	1		1.0		14.8	19.4	1.5
Indonesia					2.6	1.0	-163			
INTP.JK	Indocement	24950	7,933	1		1.0		17.8	3.0	1.9
Korea					15.6	15.5	-12			
000720.KS	Hyundai E&C	63400	6,868	1		0.5		11.5	22.3	0.8
005930.KS	Samsung Electronics	1343000	192,435	1		7.0		7.8	-15.0	1.0
005380.KS	Hyundai Motor	245500	52,605	1		3.5		6.6	-3.6	0.9
066570.KS	LG Electronics	76800	12,226	2		3.0		14.3	396.3	0.3
161390.KS	Hankook Tire	56900	6,857	1		1.5		9.0	5.8	0.7
Malaysia					3.9	2.0	-185			
UMWS.KL	UMW Holdings	11.7	4,276	1		2.0		14.3	46.5	4.2
Taiwan					11.8	21.0	916			
2330.TW	TSMC	121	104,367	1		6.0		12.3	36.0	2.5
2891.TW	Chinatrust FHC	21.1	10,327	2		2.5		12.4	15.4	3.2
2882.TW	Cathay FHC	50.4	21,063	2		2.5		17.1	20.4	2.8
Thailand					2.2	1.5	-71			
KTB.BK	Krung Thai Bank	21.5	9,335	2		1.5		9.9	-10.6	4.0

Source: Citi Research estimates
coverage.

Note: Stock weights may not add up as stocks may be removed from time to time owing to internal restrictions or discontinuation of

Figure 27. EM Model Portfolio Holding (continued)

RIC	Name	Price (local) 7/31/2014	Mkt Cap US\$mn	Ratings	Wgts (%) in MSCI EM	Model Wgts	O/U-Wgts bps	2014E PE	2014E EPS Growth (%)	2014E DivYld (%)
EMEA					17.9	12.5	-536			
	Czech Republic				0.2	0.0	-21			
	Egypt				0.2	0.0	-21			
	Hungary				0.2	0.0	-20			
	Greece				0.7	0.0	-71			
	Qatar				0.5	0.0	-45			
	United Arab Emirates				0.5	0.0	-55			
	Poland				1.5	1.0	-53			
GPW.WA	GPW	35.7	480	1		1.0		14.1	-6.4	6.0
Russia					4.7	4.5	-24			
SBER.MM	Sberbank RF	73.6	46,073	1		1.0		4.7	-7.0	4.1
SNGS_P.MM	Surgutneftegaz	26.33	30,537	1		1.0		3.2	7.4	9.0
MGNTq.L	Magnit	59	27,896	1		1.5		21.6	29.7	1.4
NVTKq.L	Novatek OAO	103.85	31,400	1		1.0		10.4	25.7	2.9
South Africa					7.5	4.0	-351			
MPTJ.J	Mpact Limited	30.11	460	2		2.0		12.5	3.0	2.8
Turkey					1.7	3.0	126			
ARCLK.IS	Arcelik	13.6	4,291	1		1.5		13.0	13.1	3.3
SISE.IS	Sisecam	3.12	2,476	1		1.5		9.7	26.3	2.4
LatAm					18.9	14.0	-489			
Colombia					1.0	0.0	-101			
Peru					0.4	0.0	-43			
Brazil					10.9	8.5	-242			
VALE.N	Vale	14.35	70,901	1		2.5		9.5	1239.1	6.1
ITUB4.SA	Itaú Unibanco	35.1	85,751	1		2.0		10.1	20.0	3.0
BRKM5.SA	Braskem	14.03	4,291	2		2.0		12.3	23.9	1.7
PBRa.N	Petrobras	16.82	106,430	2		2.0		9.3	6.2	3.2
Chile					1.4	0.5	-93			
RIP.SN	Ripley	342.7	1,160	2		0.5		15.8	-4.5	2.0
Mexico					5.1	5.0	-11			
GENTERA.MX	Gentera	26.77	3,338	1		1.5		16.8	16.1	0.0
WALMEXV.MX	Walmex	32.83	43,588	2		2.0		24.1	6.4	3.8
OHLMEX.MX	OHL Mexico	38.44	5,038	1H		1.5		10.7	-10.8	0.0

Source: Citi Research estimates
coverage.

Note: Stock weights may not add up as stocks may be removed from time to time owing to internal restrictions or discontinuation of

Appendix A-1

Analyst Certification


The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Hyundai Motor (005380.KS)

Ratings and Target Price History Fundamental Research

Analyst: Ethan Kim



	Date	Rating	Target Price	Closing Price
1	4-Oct-11	1M	*320,000.00	205,000.00
2	7-Oct-11	Stock rating system changed		
3	7-Oct-11	*1	320,000.00	200,000.00
4	23-Jul-12	1	*300,000.00	219,000.00

* Indicates change

	Date	Rating	Target Price	Closing Price
5	14-Nov-12	1	*280,000.00	216,500.00
6	18-Jan-13	1	*260,000.00	213,500.00
7	31-Jan-13	1	*254,000.00	205,000.00
8	26-Mar-13	1	*262,000.00	220,500.00

	Date	Rating	Target Price	Closing Price
9	17-Apr-13	1	*256,000.00	192,500.00
10	9-Jun-13	1	*270,000.00	208,000.00
11	1-Oct-13	1	*320,000.00	254,500.00
12	21-Jul-14	1	*300,000.00	227,500.00

Rating/target price changes above reflect Eastern Standard Time

Hyundai Motor (005380.KS)

Ratings and Target Price History Best Ideas Research Relative Call (3 Month)

Analyst: Ethan Kim



	Date	Rating	Target Price	Closing Price
1	9-Aug-11	*REM MP	-	194,000.00

* Indicates change

	Date	Rating	Target Price	Closing Price
2	7-Nov-11	*ADD MP	-	237,000.00

	Date	Rating	Target Price	Closing Price
3	25-Apr-14	*REM MP	-	236,000.00

Rating/target price changes above reflect Eastern Standard Time


Hankook Tire (161390.KS)

Ratings and Target Price History

Fundamental Research

Analyst: Ethan Kim

Covered since November 17 2012



	Date	Rating	Target Price	Closing Price
1	8-Oct-11	Stock rating system changed		
2	16-Nov-12	*1	*53,000.00	42,700.00
3	10-Jan-13	1	*56,000.00	46,600.00

* Indicates change

	Date	Rating	Target Price	Closing Price
4	24-May-13	1	*65,000.00	53,100.00
5	30-Jul-13	1	*69,000.00	58,800.00
6	27-Sep-13	1	*77,000.00	63,100.00

	Date	Rating	Target Price	Closing Price
7	7-Apr-14	1	*73,000.00	60,200.00
8	30-Apr-14	1	*69,000.00	59,700.00

Rating/target price changes above reflect Eastern Standard Time

Hankook Tire (161390.KS)

Ratings and Target Price History

Best Ideas Research

Relative Call (3 Month)

Analyst: Ethan Kim

Covered since November 17 2012



* Indicates change


Rating/target price changes above reflect Eastern Standard Time

Samsung Electronics (005930.KS)

Ratings and Target Price History

Fundamental Research

Analyst: Henry H Kim, CFA



	Date	Rating	Target Price	Closing Price
1	31-Aug-11	1L	*1,200,000.00	744,000.00
2	7-Oct-11	Stock rating system changed		
3	7-Oct-11	*1	1,200,000.00	860,000.00
4	28-Oct-11	1	*1,300,000.00	945,000.00

* Indicates change

	Date	Rating	Target Price	Closing Price
5	7-Dec-11	1	*1,400,000.00	1,056,000.00
6	16-Mar-12	1	*1,800,000.00	1,238,000.00
7	9-Apr-12	1	*1,900,000.00	1,317,000.00
8	25-Jun-12	1	*1,970,000.00	1,132,000.00

	Date	Rating	Target Price	Closing Price
9	1-Jul-13	1	*1,950,000.00	1,326,000.00
10	26-Jul-13	1	*1,900,000.00	1,303,000.00
11	7-Jan-14	1	*1,800,000.00	1,304,000.00
12	31-Jul-14	1	*1,700,000.00	1,343,000.00

Rating/target price changes above reflect Eastern Standard Time

Samsung Electronics (005930.KS)

Ratings and Target Price History

Best Ideas Research

Relative Call (3 Month)

Analyst: Henry H Kim, CFA



Date	Rating	Target Price	Closing Price
[1] 16-Mar-12	*ADD MP	-	1,238,000.00

* Indicates change

Date	Rating	Target Price	Closing Price
[2] 31-Jan-14	*REM MP	-	1,280,000.00

Rating/target price changes above reflect Eastern Standard Time

LG Electronics (066570.KS)

Ratings and Target Price History

Fundamental Research

Analyst: Henry H Kim, CFA



Date	Rating	Target Price	Closing Price
[1] 7-Oct-11	Stock rating system changed		
[2] 7-Oct-11	*1	131,931.84	72,318.20
[3] 26-Oct-11	1	*112,386.39	75,738.66
[4] 18-Nov-11	1	*112,000.00	67,200.00
[5] 17-Feb-12	1	*107,000.00	91,300.00
[6] 27-Mar-12	1	*105,000.00	86,000.00

* Indicates change

Date	Rating	Target Price	Closing Price
[7] 3-Jul-12	1	*93,000.00	63,200.00
[8] 25-Jul-12	1	*68,000.00	56,100.00
[9] 11-Oct-12	*2	*70,000.00	67,200.00
[10] 24-Oct-12	2	*75,000.00	74,000.00
[11] 15-Jan-13	2	*77,000.00	73,500.00
[12] 11-Apr-13	2	*89,000.00	86,600.00

Date	Rating	Target Price	Closing Price
[13] 9-Jul-13	2	*78,000.00	69,000.00
[14] 27-Jan-14	2	*75,000.00	68,900.00
[15] 21-Mar-14	2	*72,000.00	63,200.00
[16] 29-Apr-14	2	*80,000.00	71,700.00
[17] 24-Jul-14	2	*83,000.00	77,000.00

Rating/target price changes above reflect Eastern Standard Time

LG Electronics (066570.KS)

Ratings and Target Price History

Best Ideas Research

Relative Call (3 Month)

Analyst: Henry H Kim, CFA



Date	Rating	Target Price	Closing Price
[1] 8-Feb-12	*ADD LP	-	89,100.00

* Indicates change

Date	Rating	Target Price	Closing Price
[2] 6-Aug-13	*REM LP	-	74,900.00

Rating/target price changes above reflect Eastern Standard Time

Hyundai E&C (000720.KS)

Ratings and Target Price History

Fundamental Research

Analyst: Sungmee Park, CFA



	Date	Rating	Target Price	Closing Price
1	7-Oct-11	Stock rating system changed		
2	7-Oct-11	*1	110,000.00	57,000.00
3	20-Oct-11	1	*90,000.00	64,100.00

* Indicates change

	Date	Rating	Target Price	Closing Price
4	29-May-12	1	*83,000.00	69,900.00
5	4-Jan-13	1	*90,000.00	73,700.00
6	2-Jul-13	1	*85,000.00	56,800.00

	Date	Rating	Target Price	Closing Price
7	3-Apr-14	1	*80,000.00	56,400.00

Rating/target price changes above reflect Eastern Standard Time

Hyundai E&C (000720.KS)

Ratings and Target Price History

Best Ideas Research

Relative Call (3 Month)

Analyst: Sungmee Park, CFA



	Date	Rating	Target Price	Closing Price
1	4-Apr-13	*ADD MP	-	63,200.00

* Indicates change

	Date	Rating	Target Price	Closing Price
2	3-Apr-14	*REM MP	-	56,400.00

Rating/target price changes above reflect Eastern Standard Time

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Vale SA

Due to Citigroup Global Market Inc.'s involvement in connection with the announced public tender offer by Itaú Unibanco Holding S.A. ('Itaú') to acquire the outstanding ordinary shares of Redecard not held by Itaú or its affiliates, Citi Research restricted publication of new research reports, and suspended its rating and target price for Itaú on February 29, 2012 (the 'Suspension Date'). Please note that Itaú's price chart available on Citi Research's disclosure website does not reflect that Citi Research did not have a rating or target price between the Suspension date and June 4, 2012 when Citi Research resumed full coverage.

DMBH rating distribution versus Investment Banking service provision in the past 12 months as at 30th June 2014 is as follows: Buy (1) representing 26% of the DMBH coverage 0% of which are IB clients, Hold (2) representing 42% of the DMBH coverage 0% of which are IB clients, Sell (3) representing 32% of the DMBH coverage 0% of which are IB clients.

One or more members of the board of directors of one of the subsidiaries of Citigroup Holdings are members of the board of directors of OHL Mexico S.A.B. de CV. Citigroup Holdings or its affiliates beneficially owned 1% or more of any class of common equity securities of OHL Mexico SAB de CV at the end of at least one of the last three months.

Citi is acting as a joint lead manager for Caifu Holdings Ltd, a wholly owned subsidiary of Guangzhou R&F Properties Co's senior notes offering.

Grupo Financiero Banamex Inc. or its subsidiaries' proprietary portfolio had 1% or more of the composition invested in securities of Walmart de México at the end of at least one of the last three months One or more members of the board of directors of one of the subsidiaries of Citigroup Holdings are members of the board of directors of Wal - Mart de Mexico, S.A.B. de C.V.

Citigroup Holdings or its affiliates beneficially owned 1% or more of any class of common equity securities of Compartamos SAB de CV at the end of at least one of the last three months.

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of POSCO, OHL Mexico, Walmex, Gentera, Baidu.com, Tata Motors, AXIS Bank. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of China Construction Bank, CNOOC, Tencent Holdings, China Life Insurance, China Mobile, Petrobras, SK Hynix, ICICI Bank, Hyundai Motor, Sinopec, GPW, Industrial & Commercial Bank of China, Indocement, Bank of China, POSCO, Tata Consultancy Services, Guangzhou R&F Properties, PetroChina, Harbin Electric, Walmex, Braskem, China Unicom, Gentera, Tata Motors, SM Investments, AXIS Bank.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from China Construction Bank, TSMC, CNOOC, Siam Commercial Bank, ITC, Tencent Holdings, Vale, Arcelik AS, China Life Insurance, China Mobile, Petrobras, Astra International, Itaú Unibanco, SK Hynix, Housing Development Finance, ICICI Bank, Hyundai Motor, Sinopec, GPW, Industrial & Commercial Bank of China, Indocement, Bank of China, Infosys, POSCO, OHL Mexico, Samsung SDI, Tata Consultancy Services, Samsung Electronics, Guangzhou R&F Properties, Sberbank RF, Cairn India, PetroChina, CTBC Financial Holding, Harbin Electric, Walmex, Tenaga Nasional, Braskem, Novatek OAO, LG Chem, Reliance Industries, Ripley, China Unicom, Krung Thai Bank, Gentera, LG Electronics, HDFC Bank, Baidu.com, Tata Motors, UltraTech Cement, Bharti Airtel, Cathay FHC, Sisecam, SM Investments, Kia Motors, AXIS Bank.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from China Construction Bank, CNOOC, China Life Insurance, China Mobile, Petrobras, Hyundai Motor, Sinopec, Industrial & Commercial Bank of China, Bank of China, Samsung Electronics, Sberbank RF, PetroChina, Harbin Electric, Braskem, China Unicom, Krung Thai Bank, Kia Motors.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from China Construction Bank, TSMC, CNOOC, Siam Commercial Bank, ITC, Surgutneftegaz, Tencent Holdings, Vale, Arcelik AS, China Life Insurance, China Mobile, Petrobras, Astra International, Tingyi, Itaú Unibanco, SK Hynix, NetEase, Housing Development Finance, ICICI Bank, Hyundai Motor, Sinopec, GPW, Chunghwa Telecom, Industrial & Commercial Bank of China, Indocement, Bank of China, Infosys, POSCO, OHL Mexico, Samsung SDI, Tata Consultancy Services, Naver Corp, Hankook Tire, Samsung Electronics, Guangzhou R&F Properties, Sberbank RF, Cairn India, PetroChina, CTBC Financial Holding, Harbin Electric, Walmex, Tenaga Nasional, Braskem, Novatek OAO, LG Chem, Reliance Industries, Ripley, China Unicom, Krung Thai Bank, Gentera, LG Electronics, HDFC Bank, Baidu.com, Tata Motors, UltraTech Cement, Bharti Airtel, Cathay FHC, UMW Holdings, Sisecam, SM Investments, Kia Motors, Hyundai E&C, AXIS Bank in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as investment banking client(s): CNOOC, Sinopec, China Construction Bank, TSMC, Siam Commercial Bank, ITC, Tencent Holdings, Vale, Arcelik AS, China Life Insurance, China Mobile, Petrobras, Astra International, Itaú Unibanco, SK Hynix, Housing Development Finance, ICICI Bank, Hyundai Motor, GPW, Industrial & Commercial Bank of China, Indocement, Bank of China, Infosys, POSCO, OHL Mexico, Samsung SDI, Tata Consultancy Services, Samsung Electronics, Guangzhou R&F Properties, Sberbank RF, Cairn India, PetroChina, CTBC Financial Holding, Harbin Electric, Walmex, Tenaga Nasional, Braskem, Novatek OAO, LG Chem, Reliance Industries, Ripley, China Unicom, Krung Thai Bank, Gentera, LG Electronics, HDFC Bank, Baidu.com, Tata Motors, UltraTech Cement, Bharti Airtel, Cathay FHC, Sisecam, SM Investments, Kia Motors, AXIS Bank.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: China Construction Bank, TSMC, CNOOC, Siam Commercial Bank, ITC, Surgutneftegaz, Tencent Holdings, Vale, Arcelik AS, China Life Insurance, China Mobile, Petrobras, Astra International, Tingyi, Itaú Unibanco, SK Hynix, Housing Development Finance, ICICI Bank, Hyundai Motor, Sinopec, GPW, Chunghwa Telecom, Industrial & Commercial Bank of China, Indocement, Bank of China, Infosys, POSCO, OHL Mexico, Samsung SDI, Tata Consultancy Services, Naver Corp, Hankook Tire, Samsung Electronics, Sberbank RF, Cairn India, PetroChina, CTBC Financial Holding, Harbin Electric, Walmex, Tenaga Nasional, Braskem, Novatek OAO, LG Chem, Reliance Industries, Ripley, China Unicom, Krung Thai Bank, Gentera, LG Electronics, HDFC Bank, Baidu.com, Tata Motors, UltraTech Cement, Bharti Airtel, Cathay FHC, UMW Holdings, Sisecam, SM Investments, Kia Motors, Hyundai E&C, AXIS Bank.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, non-securities-related: China Construction Bank, TSMC, CNOOC, Siam Commercial Bank, ITC, Surgutneftegaz, Tencent Holdings, Vale, Arcelik AS, China Life Insurance, China Mobile, Petrobras, Astra International, Tingyi, Itaú Unibanco, SK Hynix, NetEase, Housing Development Finance, ICICI Bank, Hyundai Motor, Sinopec, GPW, Chunghwa Telecom, Industrial & Commercial Bank of China, Indocement, Bank of China, Infosys, POSCO, OHL Mexico, Samsung SDI, Tata Consultancy Services, Naver Corp, Hankook Tire, Samsung Electronics, Guangzhou R&F Properties, Sberbank RF, Cairn India, PetroChina, CTBC Financial Holding, Harbin Electric, Walmex, Tenaga Nasional, Braskem, Novatek OAO, LG Chem, Reliance Industries, Ripley, China Unicom, Krung Thai Bank, Gentera, LG Electronics, HDFC Bank, Baidu.com, Tata Motors, UltraTech Cement, Bharti Airtel, Cathay FHC, UMW Holdings, Sisecam, SM Investments, Kia Motors, Hyundai E&C, AXIS Bank.

Citigroup Global Markets Inc. or an affiliate received compensation in the past 12 months from CNOOC, Sinopec.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

The Firm is a market maker in the publicly traded equity securities of China Construction Bank, TSMC, CNOOC, Surgutneftegaz, Tencent Holdings, China Life Insurance, China Mobile, Tingyi, NetEase, ICICI Bank, Sinopec, Industrial & Commercial Bank of China, Bank of China, Infosys, Sberbank RF, PetroChina, Walmex, China Unicom, HDFC Bank, Baidu.com.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Research Equity Ratings Distribution

Data current as of 30 Jun 2014

	12 Month Rating			Relative Rating		
	Buy	Hold	Sell	Buy	Hold	Sell
Citi Research Global Fundamental Coverage	49%	40%	12%	0%	100%	0%
% of companies in each rating category that are investment banking clients	55%	53%	46%	0%	54%	0%

Guide to Citi Research Fundamental Research Investment Ratings:

Citi Research stock recommendations include an investment rating and an optional risk rating to highlight high risk stocks.

Risk rating takes into account both price volatility and fundamental criteria. Stocks will either have no risk rating or a High risk rating assigned.

Investment Ratings: Citi Research investment ratings are Buy, Neutral and Sell. Our ratings are a function of analyst expectations of expected total return ("ETR") and risk. ETR is the sum of the forecast price appreciation (or depreciation) plus the dividend yield for a stock within the next 12 months. The Investment rating definitions are: Buy (1) ETR of 15% or more or 25% or more for High risk stocks; and Sell (3) for negative ETR. Any covered stock not assigned a Buy or a Sell is a Neutral (2). For stocks rated Neutral (2), if an analyst believes that there are insufficient valuation drivers and/or investment catalysts to derive a positive or negative investment view, they may elect with the approval of Citi Research management not to assign a target price and, thus, not derive an ETR. Analysts may place covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and / or trading in the company's securities (e.g. trading suspension). As soon as practically possible, the analyst will publish a note re-establishing a rating and investment thesis. To satisfy regulatory requirements, we correspond Under Review and Neutral to Hold in our ratings distribution table for our 12-month fundamental rating system. However, we reiterate that we do not consider Under Review to be a recommendation.

Prior to May 1, 2014 Citi Research may have also assigned a three-month relative call (or rating) to a stock to highlight expected out-performance (most preferred) or under-performance (least preferred) versus the geographic and industry sector over a 3 month period. The relative call may have highlighted a specific near-term catalyst or event impacting the company or the market that was anticipated to have a short-term price impact on the equity securities of the company. Absent any specific catalyst the analyst(s) may have indicated the most and least preferred stocks in the universe of stocks under consideration, explaining the basis for this short-term view. This three-month view may have been different from and did not affect a stock's fundamental equity rating, which reflected a longer-term total absolute return expectation. For purposes of NASD/NYSE ratings-distribution-disclosure rules, most preferred calls corresponded to a buy recommendation and least preferred calls corresponded to a sell recommendation. Any stock not assigned to a most preferred or least preferred call was considered non-relative-rated (NRR). For purposes of NASD/NYSE ratings-distribution-disclosure rules we corresponded NRR to Hold in our ratings distribution table for our 3-month relative rating system. However, we reiterate that we did not consider NRR to be a recommendation.

Prior to October 8, 2011, the firm's stock recommendation system included a risk rating and an investment rating. **Risk ratings**, which took into account both price volatility and fundamental criteria, were: Low (L), Medium (M), High (H), and Speculative (S). **Investment Ratings** of Buy, Hold and Sell were a function of the Citi Research expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating. Additionally, analysts could have placed covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and/or trading in the company's securities (e.g. trading suspension). Stocks placed "Under Review" were monitored daily by management and as practically possible, the analyst published a note re-establishing a rating and investment thesis. For securities in developed markets (US, UK, Europe, Japan, and Australia/New Zealand), investment ratings were: Buy (1) (expected total return of 10% or more for Low-Risk stocks, 15% or more for Medium-Risk stocks, 20% or more for High-Risk stocks, and 35% or more for Speculative stocks); Hold (2) (0%-10% for Low-Risk stocks, 0%-15% for Medium-Risk stocks, 0%-20% for High-Risk stocks, and 0%-35% for Speculative stocks); and Sell (3) (negative total return). For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings were: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Asia	Markus Rosgen; Yue Hin Pong; Mandy Ym Chan; Jasmine Bai; Graham Cunningham; Oscar Yee; Thomas Chong; Bin Liu; Simon Ho, CFA; Pierre Lau, CFA; Darwin Lam, CFA; Oscar Choi; Gary Lam
Citigroup Global Markets Korea Securities Ltd	Ethan Kim; Henry H Kim, CFA; Sungmee Park, CFA; Irene Cho
Citigroup Global Markets Taiwan Securities Co. Limited	Roland Shu; Timothy Chen; Peter Kurz
Citibank Anonim Sirketi	Mehmet Colakoglu, CFA
PT Citigroup Securities Indonesia	Ferry Wong, CFA; Felicia Asrinanda Barus
Citigroup Global Markets India Private Limited	Aditya Narain, CFA; Gaurav Malhotra, CFA; Saurabh Handa; Surendra Goyal, CFA; Raashi Chopra, CFA
Citigroup Global Markets Brazil	Pedro Medeiros
Citigroup Global Markets Inc	Daniel A. Abut; Stephen Trent; Julio R. Zamora; Alexander Hacking, CFA
Dom Maklerski Banku Handlowego SA	Andrzej Powierza
Citigroup Global Markets Singapore PTE LIMITED	Jamshed Dadabhoy
Citicorp Securities (Thailand) Ltd.	Kritapas Siripassorn, CFA
ZAO Citibank	Brady Martin, CFA; Ronald Paul Smith
Citigroup Global Markets (Pty) Ltd	Kgosietsile S Rahube
Citigroup Global Markets Ltd	Simon Nellis

Citigroup Financial Services and Insurance Brokerage
Philippines, Inc

Minda A. Olanon

Citigroup Global Markets Malaysia SDN BHD

Petrina Chong; Lawrence Ye

OTHER DISCLOSURES

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to China Construction Bank, TSMC, ITC, Vale, Astra International, Housing Development Finance, ICICI Bank, Hyundai Motor, Bank of China, Samsung Electronics, Braskem, LG Chem, Reliance Industries, China Unicom, HDFC Bank, Tata Motors, Kia Motors, AXIS Bank. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citiVelocity.com.)

Citigroup Global Markets Inc. or its affiliates beneficially owns 2% or more of any class of common equity securities of OHL Mexico.

Citigroup Global Markets Inc. or its affiliates beneficially owns 5% or more of any class of common equity securities of Gentera.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Bell Potter Customers: Bell Potter is making this Product available to its clients pursuant to an agreement with Citigroup Global Markets Australia Pty Limited. Neither Citigroup Global Markets Australia Pty Limited nor any of its affiliates has made any determination as to the suitability of the information provided herein and clients should consult with their Bell Potter financial advisor before making any investment decision.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in **Australia** through Citigroup Global Markets Australia Pty Limited. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its

clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. 1202, 12th Floor, FIFC, G Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051 Corporate Identity Number: U99999MH2000PTC126657 Tel:+9102261759999 Fax:+9102261759961. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A., Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised by the PRA and regulated by the FCA and the PRA. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ("FAA") through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to

purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 399 Interchange 21 Building, 18th Floor, Sukhumvit Road, Klongtoey Nua, Wattana, Bangkok 10110, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA. This material may relate to investments or services of a person outside of the UK or to other matters which are not authorised by the PRA nor regulated by the FCA and the PRA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is authorised by the PRA and regulated by the FCA and the PRA.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. Citi Research generally disseminates its research to the Firm's global institutional and retail clients via both proprietary (e.g., Citi Velocity and Citi Personal Wealth Management) and non-proprietary electronic distribution platforms. Certain research may be disseminated only via Citi's proprietary distribution platforms; however such research will not contain changes to earnings forecasts, target price, investment or risk rating or investment thesis or be otherwise inconsistent with the author's previously published research. Certain research is made available only to institutional investors to satisfy regulatory requirements. Individual Citi Research analysts may also opt to circulate published research to one or more clients by email; such email distribution is discretionary and is done only after the research has been disseminated.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Thomson Reuters.

© 2014 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST